-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Bionomics Limited (NASDAQ:BNOX) Given Consensus Rating of "Moderate Buy" by Analysts
Bionomics Limited (NASDAQ:BNOX) Given Consensus Rating of "Moderate Buy" by Analysts
Bionomics Limited (NASDAQ:BNOX – Get Rating) has been given a consensus rating of "Moderate Buy" by the six analysts that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $16.67.
BNOX has been the subject of a number of recent analyst reports. Evercore ISI reaffirmed an "in-line" rating and issued a $6.00 price objective (down previously from $17.00) on shares of Bionomics in a research report on Tuesday. Loop Capital initiated coverage on Bionomics in a research report on Tuesday, November 1st. They issued a "buy" rating and a $23.00 price objective for the company. Finally, HC Wainwright downgraded Bionomics from a "buy" rating to a "neutral" rating in a research report on Monday.
Get Bionomics alerts:Bionomics Stock Down 16.1 %
Shares of NASDAQ:BNOX opened at $4.94 on Wednesday. Bionomics has a 52 week low of $4.94 and a 52 week high of $13.76. The business has a fifty day simple moving average of $7.62 and a 200-day simple moving average of $7.37.
About Bionomics
(Get Rating)Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.
Featured Articles
- Get a free copy of the StockNews.com research report on Bionomics (BNOX)
- Is There a Prize in Store for Kellogg Shareholders?
- Will AMC's Troubles Affect Its Landlord, EPR Properties?
- General Mills Retreats To More Attractive Territory
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- Can Chewy Fetch Double Digit Gains in 2023?
Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.
Bionomics Limited (NASDAQ:BNOX – Get Rating) has been given a consensus rating of "Moderate Buy" by the six analysts that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $16.67.
據MarketBeat Ratings報道,生物科技有限公司(納斯達克代碼:BNOX-GET Rating)目前追蹤該公司的六位分析師一致給予該公司“中等買入”的評級。兩名股票研究分析師將該股評級為持有,四名分析師給予該公司買入評級。在去年更新了該股覆蓋範圍的券商中,12個月目標價的平均水準為16.67美元。
BNOX has been the subject of a number of recent analyst reports. Evercore ISI reaffirmed an "in-line" rating and issued a $6.00 price objective (down previously from $17.00) on shares of Bionomics in a research report on Tuesday. Loop Capital initiated coverage on Bionomics in a research report on Tuesday, November 1st. They issued a "buy" rating and a $23.00 price objective for the company. Finally, HC Wainwright downgraded Bionomics from a "buy" rating to a "neutral" rating in a research report on Monday.
BNOX一直是最近多份分析師報告的主題。Evercore ISI在週二的一份研究報告中重申了對Bionomics的評級,併發布了6.00美元的目標價(低於此前的17.00美元)。Loop Capital在11月1日(星期二)的一份研究報告中啟動了對生物學的報道。他們對該公司的評級為“買入”,目標價為23.00美元。最後,在週一的一份研究報告中,HC Wainwright將Bionomics的評級從“買入”下調至“中性”。
Bionomics Stock Down 16.1 %
生物類股下跌16.1%
Shares of NASDAQ:BNOX opened at $4.94 on Wednesday. Bionomics has a 52 week low of $4.94 and a 52 week high of $13.76. The business has a fifty day simple moving average of $7.62 and a 200-day simple moving average of $7.37.
週三,納斯達克的股價開盤報4.94美元。Bionomics的52周低點為4.94美元,52周高點為13.76美元。該業務的50日簡單移動均線為7.62美元,200日簡單移動均線為7.37美元。
About Bionomics
關於生物學
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.
生物製藥有限公司是一家臨床階段的生物製藥公司,發現和開發治療中樞神經系統疾病和癌症的新藥候選藥物。該公司的主要候選藥物包括BNC210,這是一種A7菸鹼型乙酰膽鹼受體的負變構調節劑,正處於治療社交焦慮障礙的第二階段臨床試驗和治療創傷後應激障礙的2b階段臨床試驗。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Bionomics (BNOX)
- Is There a Prize in Store for Kellogg Shareholders?
- Will AMC's Troubles Affect Its Landlord, EPR Properties?
- General Mills Retreats To More Attractive Territory
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- Can Chewy Fetch Double Digit Gains in 2023?
- 免費獲取StockNews.com關於生物學的研究報告(BNOX)
- 凱洛格的股東有店內獎品嗎?
- AMC的麻煩會影響其房東EPR Properties嗎?
- 通用磨坊撤退至更具吸引力的地區
- 如果馬斯克退出Twitter,特斯拉的股價會上漲嗎?
- Chewy能否在2023年獲得兩位數的增長?
Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《生物學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Bionomics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧